SCYNEXIS, Inc.
SCYX
Positions held
Your positionsSCYX isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $41.99M | Enterprise value | -$10.15M | Trailing P/E | — | Forward P/E | -1.82 |
| PEG | — | Price / book | 0.63 | Beta | 1.06 | Dividend yield | 0.00% |
| Revenue growth | -82.8% | Earnings growth | — | Gross margin | 100.0% | Operating margin | -33.1% |
| Profit margin | -53.3% | ROE | -18.4% | ROA | -20.8% | Debt / equity | 0.03 |
| Current ratio | 9.65 | Free cash flow | -$7.32M | Analyst recommendation | strong_buy | Mean target | $36.33 |
| 52w high | $9.12 | 52w low | $3.53 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.2M | $0.0M | $18.6M | $0.3M | $1.4M | — |
| Op margin | -3308.5% | — | 56.4% | -2516.5% | -701.0% | — |
| Net income | $7.4M | -$21.3M | $12.3M | -$8.6M | -$6.9M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$7.8M | -$16.9M | $10.5M | -$8.4M | -$9.6M | — |
- Operating margin compressed to -3308.5%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $20.6M | $3.7M | $140M | $5.1M | — |
| Op margin | -78.0% | -990.8% | 51.9% | -1684.5% | — |
| Net income | -$8.6M | -$21.3M | $67.0M | -$62.8M | — |
| Gross margin | — | 100.0% | 88.9% | 87.7% | — |
| Gross profit | — | $3.7M | $125M | $4.5M | $12.9M |
| Operating income | -$16.1M | -$37.1M | $72.7M | -$85.8M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-28 · Scynexis stock surges on $214M BARDA contract for SCY-247
2026-09-28 · Scynexis Shares Rise 13.9% After BARDA Awards SCY-247 Development Contract
2026-09-28 · SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247
2026-09-22 · SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors
2026-09-15 · SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development
2026-09-10 · SCYNEXIS Names Sanjay Subramanian as CFO
2026-09-10 · SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer
2026-09-01 · SCYNEXIS to Participate in Upcoming Investor Conferences
2026-08-25 · SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
2026-08-10 · Scynexis: Q2 Earnings Snapshot
2026-08-10 · SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Price (daily)
Full chart · RSI · MACD · patterns